Keystone Financial Services Takes Position in Insulet Co. (NASDAQ:PODD)

Keystone Financial Services bought a new stake in Insulet Co. (NASDAQ:PODD) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 902 shares of the medical instruments supplier’s stock, valued at approximately $210,000.

A number of other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of Insulet by 2.1% in the first quarter. Vanguard Group Inc. now owns 8,199,114 shares of the medical instruments supplier’s stock valued at $1,405,328,000 after purchasing an additional 169,506 shares during the period. Baillie Gifford & Co. grew its holdings in Insulet by 30.8% during the second quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock worth $380,607,000 after acquiring an additional 443,783 shares during the period. Clearbridge Investments LLC grew its holdings in Insulet by 6.0% during the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock worth $270,364,000 after acquiring an additional 75,526 shares during the period. American Century Companies Inc. grew its holdings in Insulet by 18.7% during the second quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier’s stock worth $178,728,000 after acquiring an additional 139,246 shares during the period. Finally, Marshall Wace LLP acquired a new position in Insulet during the second quarter worth $99,978,000.

Analyst Upgrades and Downgrades

PODD has been the topic of a number of recent analyst reports. BTIG Research upped their price objective on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday. Raymond James upped their price objective on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Barclays upped their price objective on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday. Sanford C. Bernstein initiated coverage on Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price on the stock. Finally, Citigroup upped their target price on Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $253.27.

Insulet Stock Performance

NASDAQ PODD opened at $275.70 on Tuesday. The business’s 50-day moving average price is $233.46 and its 200 day moving average price is $205.26. Insulet Co. has a twelve month low of $156.00 and a twelve month high of $279.40. The company has a market capitalization of $19.33 billion, a PE ratio of 47.21, a price-to-earnings-growth ratio of 5.00 and a beta of 1.22. The company has a current ratio of 3.60, a quick ratio of 2.71 and a debt-to-equity ratio of 1.36.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.